Benzinga | Dec 16, 2020 10:29AM EST

Mizuho Initiates Coverage On Axsome Therapeutics with Buy Rating, Announces Price Target of $120

Mizuho analyst Vamil Divan initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Buy rating and announces Price Target of $120.